The prognostic significance of TP53 mutations in patients with DLCBL. (A) OS (in years) after treatment with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen among patients with a p53 mutation versus those with WT-p53. (B) OS (in months) after treatment with the rituximab-CHOP regimen among patients with p53 mutations versus those with WT-p53. (C) OS (in years) after CHOP treatment among patients with a TP53 DNA-binding domain mutation versus those with WT-p53. (D) Location of critical p53 residues in the p53 domain model designed from the published crystal structure. The mutations depicted are associated with poor outcome identified from our group study in 1187 DLBCL cases. The residues are color-coded as follows: green represents mutation from or to proline; deep blue, residues close to zinc sites; light blue, residues close to DNA-binding sites; brown, residues far from both zinc and DNA; and orange, cysteine residues implicated in the oxidation-reduction activity of p53.